DONQ52

Phase 2Small molecule

Roche

DONQ52 is one of 12 small molecule programs targeting Celiac Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Celiac DiseaseRecruiting

Celiac DiseasePhase 2

Recruiting

Competition

Competitive Landscape

15 competitors in Celiac Disease

#DrugCompanyPhaseTrials

Tylenol

KKenvue Brands

Approved

1 2

Advil

KKenvue Brands

Approved

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

—4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

VIOKACE

DDigestive Care, Inc.

Approved

1 6

Xifaxan

SSalix

Preclinical

1 7

DONQ52

Roche

Phase 2

2 8

Hepatitis B Vaccine

Sanofi

Preclinical

1 9

FB102

FForte Biosciences, Inc.

Phase 2

1 10

ZED1227

DDr. Falk Pharma GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Celiac Disease

NCT07239336

Clinical

Trials by Indication[1]

Celiac Disease2 trials

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

Completed· Roche logo

Roche·Phase 1·NCT05425446·56 enrolled

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)

Recruiting· Roche logo

Roche·Phase 2·NCT07239336·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DONQ52. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DONQ52 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DONQ52. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

DONQ52

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Celiac Disease2 trials

References

Drug Info

Quick Facts

Related News